“
BMS is a good company overall
, with a competitive salary and benefits and a reasonable pipeline. It is possible to get leadership/autonomous roles under the right circumstances, although this is inconsistent. The work was always interesting.”
Does Bristol Myers Squibb pay well?
The average employee at Bristol-Myers Squibb earns a
yearly salary of $97,028 per year
, but different jobs can earn drastically different salaries. Some of the positions that earn high wages at Bristol-Myers Squibb include medical director, associate director, medical science liaison, and district business manager.
Is it hard to get a job at Bristol Myers Squibb?
On Glassdoor, Bristol-Myers Squibb’s
interview process was ranked average in difficulty
and 67 percent of respondents indicated a positive experience. … Another candidate, this one for an Analyst who accepted the position, indicated it was a positive experience but a difficult interview.
What is Bristol Myers Squibb known for?
Bristol Myers Squibb
manufactures prescription pharmaceuticals and biologics
in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. … BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).
Why do you want to work for Bristol Myers Squibb?
Bristol Myers Squibb gives you
the opportunity to learn and grow professionally
alongside smart, creative and talented colleagues who are committed to helping patients battle serious diseases. Doing amazing things with people you like and admire isn’t something you can find just anywhere.
How big is BMS?
Bristol-Myers Squibb (BMS) is one of the largest pharmaceutical companies in the world, with
25,000 employees
and $19.4 billion in revenue in 2016.
How many employees does BMS have?
In 2020, the company had
over 30 thousand employees
. Bristol-Myers Squibb is headquartered in New York City and is one of the largest pharmaceutical companies worldwide.
What drugs do BMS make?
- ABECMA
®
(idecabtagene vicleucel) … - ABRAXANE
®
(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) … - AZACTAM
®
(aztreonam for injection, USP) … - BREYANZI
®
(lisocabtagene maraleucel) … - BARACLUDE
®
(entecavir) … - DROXIA
®
(hydroxyurea) … - ELIQUIS
®
(apixaban) … - EMPLICITI
®
(elotuzumab)
Why did Bristol Myers discontinue Coumadin?
The manufacturing of all strengths of Coumadin (warfarin sodium) tablets has been discontinued. As announced by Bristol-Myers Squibb, Coumadin’s manufacturer, the discontinuation is
due to an unexpected manufacturing issue
, not because of safety or efficacy issues.
Who is the owner of Bristol Myers Squibb?
Giovanni Caforio
, Bristol Myers Squibb chairman and CEO, joined “Squawk on the Street” to discuss the progress in cancer research and the companies pipeline.
Does BMS offer pension?
Pharmaceutical giant Bristol-Myers Squibb is terminating its US Retirement Income Plan, and will transfer $3.8 billion of its US pension obligations through a combination of lump sums and a group annuity contract from Athene Annuity and Life Company. …
Does BMS have a pension plan?
The
firm is terminating its pension plan
via a combination of lump-sum distributions and an annuity purchase. Bristol-Myers Squibb Company will transfer $3.8 billion of U.S. pension obligations through a full termination of its plan.
What does BMS specialize in?
Bristol Myers Squibb is committed to discovering, developing and delivering transformational medicines in areas where we believe we have an opportunity to make a meaningful difference for patients:
oncology, immunoscience, cardiovascular and fibrosis
.
What does BMS mean on TikTok?
BMS stands for “
broke my scale
” on social media. However, it doesn’t refer to a weight scale. Users are actually talking about their attractiveness scales. You can expect to see “BMS” in the TikTok comment section when somebody finds the creator to be physically pleasing.
Is BMY undervalued?
Shares of BMY
are vastly undervalued
and present a tremendous opportunity for long-term investors. Investors earn a 3% dividend that was last increased over 9% in December of last year.
